Cargando…
UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib
Anlotinib, as a promising oral small-molecule antitumor drug, its role in glioma has been only reported in a small number of case reports. Therefore, anlotinib has been considered as a promising candidate in glioma. The aim of this study was to investigate the metabolic network of C6 cells after exp...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192199/ https://www.ncbi.nlm.nih.gov/pubmed/37198251 http://dx.doi.org/10.1038/s41598-023-34902-5 |
_version_ | 1785043578905427968 |
---|---|
author | Shi, Yingying Li, Zhuolun Du, Qiuzheng Li, Wenxi Liu, Jiyun Jia, Qingquan Xue, Lianping Zhang, Xiaojian Sun, Zhi |
author_facet | Shi, Yingying Li, Zhuolun Du, Qiuzheng Li, Wenxi Liu, Jiyun Jia, Qingquan Xue, Lianping Zhang, Xiaojian Sun, Zhi |
author_sort | Shi, Yingying |
collection | PubMed |
description | Anlotinib, as a promising oral small-molecule antitumor drug, its role in glioma has been only reported in a small number of case reports. Therefore, anlotinib has been considered as a promising candidate in glioma. The aim of this study was to investigate the metabolic network of C6 cells after exposure to anlotinib and to identify anti-glioma mechanism from the perspective of metabolic reprogramming. Firstly, CCK8 method was used to evaluate the effects of anlotinib on cell proliferation and apoptosis. Secondly, ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomic and lipidomic were developed to characterize the metabolite and lipid changes in cell and cell culture medium (CCM) caused by anlotinib in the treatment of glioma. As a result, anlotinib had concentration-dependent inhibitory effect with the concentration range. In total, twenty-four and twenty-three disturbed metabolites in cell and CCM responsible for the intervention effect of anlotinib were screened and annotated using UHPLC-HRMS. Altogether, seventeen differential lipids in cell were identified between anlotinib exposure and untreated groups. Metabolic pathways, including amino acid metabolism, energy metabolism, ceramide metabolism, and glycerophospholipid metabolism, were modulated by anlotinib in glioma cell. Overall, anlotinib has an effective treatment against the development and progression of glioma, and these remarkable pathways can generate the key molecular events in cells treated with anlotinib. Future research into the mechanisms underlying the metabolic changes is expected to provide new strategies for treating glioma. |
format | Online Article Text |
id | pubmed-10192199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101921992023-05-19 UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib Shi, Yingying Li, Zhuolun Du, Qiuzheng Li, Wenxi Liu, Jiyun Jia, Qingquan Xue, Lianping Zhang, Xiaojian Sun, Zhi Sci Rep Article Anlotinib, as a promising oral small-molecule antitumor drug, its role in glioma has been only reported in a small number of case reports. Therefore, anlotinib has been considered as a promising candidate in glioma. The aim of this study was to investigate the metabolic network of C6 cells after exposure to anlotinib and to identify anti-glioma mechanism from the perspective of metabolic reprogramming. Firstly, CCK8 method was used to evaluate the effects of anlotinib on cell proliferation and apoptosis. Secondly, ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomic and lipidomic were developed to characterize the metabolite and lipid changes in cell and cell culture medium (CCM) caused by anlotinib in the treatment of glioma. As a result, anlotinib had concentration-dependent inhibitory effect with the concentration range. In total, twenty-four and twenty-three disturbed metabolites in cell and CCM responsible for the intervention effect of anlotinib were screened and annotated using UHPLC-HRMS. Altogether, seventeen differential lipids in cell were identified between anlotinib exposure and untreated groups. Metabolic pathways, including amino acid metabolism, energy metabolism, ceramide metabolism, and glycerophospholipid metabolism, were modulated by anlotinib in glioma cell. Overall, anlotinib has an effective treatment against the development and progression of glioma, and these remarkable pathways can generate the key molecular events in cells treated with anlotinib. Future research into the mechanisms underlying the metabolic changes is expected to provide new strategies for treating glioma. Nature Publishing Group UK 2023-05-17 /pmc/articles/PMC10192199/ /pubmed/37198251 http://dx.doi.org/10.1038/s41598-023-34902-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Shi, Yingying Li, Zhuolun Du, Qiuzheng Li, Wenxi Liu, Jiyun Jia, Qingquan Xue, Lianping Zhang, Xiaojian Sun, Zhi UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
title | UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
title_full | UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
title_fullStr | UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
title_full_unstemmed | UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
title_short | UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
title_sort | uhplc-hrms-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192199/ https://www.ncbi.nlm.nih.gov/pubmed/37198251 http://dx.doi.org/10.1038/s41598-023-34902-5 |
work_keys_str_mv | AT shiyingying uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT lizhuolun uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT duqiuzheng uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT liwenxi uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT liujiyun uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT jiaqingquan uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT xuelianping uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT zhangxiaojian uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib AT sunzhi uhplchrmsbasedmetabolomicandlipidomiccharacterizationofgliomacellsinresponsetoanlotinib |